Pieris Historical Income Statement
| PIRS Stock | USD 11.72 0.12 1.03% |
Historical analysis of Pieris Pharmaceuticals income statement accounts such as Depreciation And Amortization of 1.9 M, Total Revenue of 25.4 M, Gross Profit of 43.1 M or Research Development of 36.8 M can show how well Pieris Pharmaceuticals performed in making a profits. Evaluating Pieris Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Pieris Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Pieris Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Pieris Pharmaceuticals is a good buy for the upcoming year.
Pieris |
About Pieris Income Statement Analysis
Pieris Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Pieris Pharmaceuticals shareholders. The income statement also shows Pieris investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Pieris Pharmaceuticals Income Statement Chart
Pieris Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting Pieris's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Pieris Pharmaceuticals revenue and expense. Pieris Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Pieris Pharmaceuticals' Interest Expense is comparatively stable compared to the past year. Depreciation And Amortization is likely to gain to about 1.9 M in 2024, whereas Other Operating Expenses is likely to drop slightly above 46.1 M in 2024. Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Pieris Pharmaceuticals. It is also known as Pieris Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Total Revenue
Total revenue comprises all receipts Pieris Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Most accounts from Pieris Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Pieris Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pieris Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Pieris Stock please use our How to Invest in Pieris Pharmaceuticals guide.At this time, Pieris Pharmaceuticals' Interest Expense is comparatively stable compared to the past year. Depreciation And Amortization is likely to gain to about 1.9 M in 2024, whereas Other Operating Expenses is likely to drop slightly above 46.1 M in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Total Revenue | 31.4M | 25.9M | 42.8M | 25.4M | Depreciation And Amortization | 3.7M | 8.2M | 1.8M | 1.9M |
Pieris Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
Pieris Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Pieris Pharmaceuticals income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 1.7M | 3.1M | 6.1M | 10.2M | 11.7M | 12.3M | |
| Selling General Administrative | 18.4M | 16.7M | 16.6M | 16.4M | 16.9M | 13.5M | |
| Other Operating Expenses | 73.4M | 63.2M | 79.6M | 61.2M | 58.7M | 46.1M | |
| Operating Income | (27.2M) | (33.9M) | (51.8M) | (43.5M) | (15.8M) | (16.6M) | |
| Ebit | (27.2M) | (33.9M) | (51.8M) | (43.5M) | (15.8M) | (16.6M) | |
| Total Operating Expenses | 73.4M | 63.2M | 79.6M | 61.2M | 56.9M | 45.9M | |
| Income Before Tax | (25.5M) | (37.1M) | (45.7M) | (33.3M) | (24.5M) | (25.8M) | |
| Net Income | (23.8M) | (37.2M) | (43.4M) | (31.3M) | (24.5M) | (25.8M) | |
| Depreciation And Amortization | 1.0M | 2.1M | 3.7M | 8.2M | 1.8M | 1.9M | |
| Total Revenue | 46.3M | 29.3M | 31.4M | 25.9M | 42.8M | 25.4M | |
| Gross Profit | (8.7M) | (17.2M) | 29.1M | 23.1M | 41.0M | 43.1M | |
| Net Income From Continuing Ops | (25.5M) | (37.2M) | (45.7M) | (33.3M) | (28.1M) | (29.5M) | |
| Research Development | 55.0M | 46.5M | 66.7M | 53.0M | 40.0M | 36.8M | |
| Ebitda | (26.1M) | (31.8M) | (48.1M) | (35.3M) | (14.1M) | (14.8M) | |
| Cost Of Revenue | 55.0M | 46.5M | 2.4M | 2.8M | 1.8M | 1.7M | |
| Total Other Income Expense Net | 1.7M | (3.1M) | 6.1M | 10.2M | (8.7M) | (8.3M) | |
| Net Income Applicable To Common Shares | (26.8M) | (28.3M) | (37.2M) | (45.7M) | (41.2M) | (39.1M) | |
| Income Tax Expense | (1.7M) | 164K | (2.4M) | (2.0M) | (1.8M) | (1.7M) | |
| Non Operating Income Net Other | 1.8M | (26K) | (3.7M) | 2.4M | 2.8M | 2.9M | |
| Interest Income | 1.7M | 511K | 4K | 721K | 1.7M | 1.8M | |
| Net Interest Income | 1.7M | 511K | 4K | 721K | 1.7M | 936.8K | |
| Reconciled Depreciation | 1.0M | 2.1M | 2.4M | 2.8M | 2.6M | 1.9M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Pieris Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Pieris Pharmaceuticals' short interest history, or implied volatility extrapolated from Pieris Pharmaceuticals options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pieris Pharmaceuticals using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pieris Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Pieris Stock please use our How to Invest in Pieris Pharmaceuticals guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Complementary Tools for Pieris Stock analysis
When running Pieris Pharmaceuticals' price analysis, check to measure Pieris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pieris Pharmaceuticals is operating at the current time. Most of Pieris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pieris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pieris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pieris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |
Is Pieris Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pieris Pharmaceuticals. If investors know Pieris will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pieris Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (21.60) | Revenue Per Share 38.026 | Quarterly Revenue Growth (0.78) | Return On Assets (0.15) | Return On Equity (0.90) |
The market value of Pieris Pharmaceuticals is measured differently than its book value, which is the value of Pieris that is recorded on the company's balance sheet. Investors also form their own opinion of Pieris Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Pieris Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pieris Pharmaceuticals' market value can be influenced by many factors that don't directly affect Pieris Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pieris Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pieris Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pieris Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.